FOLH1 and prostate carcinoma: Therefore, radionuclides targeting these peptides, such as [68Ga]Ga-PSMA-11 ligand positron emission tomography (68Ga-PSMA PET), which is widely applied as a non-invasive molecular method for imaging prostate cancer, and [177Lu]Lu-PSMA-617 radio-ligand therapy (PSMA-RLT), which has emerged as a valuable treatment in patients with mCRPC, are currently available.